Pharmacology
Conference Coverage
Anti-CGRP monoclonal antibody offers relief from migraine and comorbid depression
“If the patient has migraine and depression and you treat with fremanezumab, both disorders get better to a statistically significant degree.”
News
Myasthenia gravis drug gets FDA nod
Rozanolixizumab is the first FDA-approved treatment for adults with both subtypes.
News
FDA approves ritlecitinib for ages 12 and up for alopecia areata
It is the second JAK inhibitor approved for treating alopecia areata, following approval of baricitinib (Olumiant) in June 2022 for alopecia...
News
FDA approves talazoparib for metastatic prostate cancer
The new approval is based on findings from the randomized, placebo-controlled, phase 3 TALAPRO-2 trial.
News
Can a repurposed Parkinson’s drug slow ALS progression?
One expert interviewed for this article said the study “falls short of being a credible 1/2a clinical trial.”
News
Starting indicated heart failure meds in-hospital: Progress, opportunities
The finding suggests that “heart failure hospitalization is, in and of itself, an important intervention for getting folks on the appropriate...
News
SSRI improves cognition, major depression in early dementia
Improvements in depressive symptoms were irrespective of dementia type.
News
FDA OKs empagliflozin for children with type 2 diabetes
This approval represents only the second oral treatment option for children and adolescents with type 2 diabetes after metformin.
Conference Coverage
Gilteritinib maintenance reduces relapse in MRD+ AML
Despite not meeting its primary endpoint, a trial in mutated acute myeloid leukemia showed the benefit of gilteritinib maintenance in certain...
News
FDA OKs low-dose colchicine for broad CV indication
“The FDA approval of colchicine for patients with atherosclerotic disease is a huge signal that physicians need to be aware of inflammation as a...